Popular Trials
Genetic Testing
Screening Method for Lynch Syndrome in Endometrial and Ovarian Cancer
This trial will test a new way of identifying women with Lynch Syndrome, a hereditary disease that can lead to cancer. If successful, it could improve screening and surgery options for women at risk.
Monoclonal Antibodies
Combination Immunotherapy for Colorectal Cancer
This trial is testing two special drugs that help the immune system fight a specific type of cancer. The drugs are given to see if they can shrink the cancer. The study focuses on patients who might not respond well to other treatments. The goal is to see if these drugs are safe and effective.
CAR T-cell Therapy
TC-510 Cell Therapy for Cancer
This trial tests TC-510, a therapy using a patient's own modified T cells to target and attack cancer cells. It is aimed at patients with cancers that are hard to treat with standard methods. The modified T cells are designed to recognize specific proteins on cancer cells and get an extra boost to kill them.
Popular Filters
Trials for Colorectal Cancer Patients
Small Molecule Inhibitor
LY3537982 for Cancer
This trial is testing a new drug called LY3537982 in cancer patients with the KRAS G12C mutation. It targets this mutation to stop cancer cells from growing. The study includes patients who haven't responded to other treatments or cannot tolerate them. LY3537982 is a new drug targeting the KRAS G12C mutation, similar to previously approved drugs like sotorasib and adagrasib.
AH-HA EHR Tool for Heart Health in Cancer Survivors
This trial is looking at the effects of a tool that uses electronic health records to help cancer survivors manage their cardiovascular health. The study will compare how well the tool works compared to usual care in terms of risk reduction and health promotion activities.
Small Molecule Inhibitor
RGX-202-01 Combination Therapy for Colorectal Cancer
This trial is testing a new drug, RGX-202-01, to see if it can shrink tumors in people with gastrointestinal cancer. The study will test different doses of the drug to see what is safe and effective. The study will also test the drug in combination with other drugs that are commonly used to treat gastrointestinal cancer.
Trials for Colon Cancer Patients
Small Molecule Inhibitor
LY3537982 for Cancer
This trial is testing a new drug called LY3537982 in cancer patients with the KRAS G12C mutation. It targets this mutation to stop cancer cells from growing. The study includes patients who haven't responded to other treatments or cannot tolerate them. LY3537982 is a new drug targeting the KRAS G12C mutation, similar to previously approved drugs like sotorasib and adagrasib.
AH-HA EHR Tool for Heart Health in Cancer Survivors
This trial is looking at the effects of a tool that uses electronic health records to help cancer survivors manage their cardiovascular health. The study will compare how well the tool works compared to usual care in terms of risk reduction and health promotion activities.
Small Molecule Inhibitor
RGX-202-01 Combination Therapy for Colorectal Cancer
This trial is testing a new drug, RGX-202-01, to see if it can shrink tumors in people with gastrointestinal cancer. The study will test different doses of the drug to see what is safe and effective. The study will also test the drug in combination with other drugs that are commonly used to treat gastrointestinal cancer.
Trials for Metastatic Patients
Small Molecule Inhibitor
LY3537982 for Cancer
This trial is testing a new drug called LY3537982 in cancer patients with the KRAS G12C mutation. It targets this mutation to stop cancer cells from growing. The study includes patients who haven't responded to other treatments or cannot tolerate them. LY3537982 is a new drug targeting the KRAS G12C mutation, similar to previously approved drugs like sotorasib and adagrasib.
Small Molecule Inhibitor
RGX-202-01 Combination Therapy for Colorectal Cancer
This trial is testing a new drug, RGX-202-01, to see if it can shrink tumors in people with gastrointestinal cancer. The study will test different doses of the drug to see what is safe and effective. The study will also test the drug in combination with other drugs that are commonly used to treat gastrointestinal cancer.
PD-L1 Inhibitor
Durvalumab + Olaparib + Cediranib for Ovarian Cancer
This trial is testing the combination of Durvalumab, Olaparib, and Cediranib in adults with advanced or recurrent ovarian cancer to see how well they tolerate it and if it is effective in treating the cancer.
Trials With No Placebo
Small Molecule Inhibitor
LY3537982 for Cancer
This trial is testing a new drug called LY3537982 in cancer patients with the KRAS G12C mutation. It targets this mutation to stop cancer cells from growing. The study includes patients who haven't responded to other treatments or cannot tolerate them. LY3537982 is a new drug targeting the KRAS G12C mutation, similar to previously approved drugs like sotorasib and adagrasib.
AH-HA EHR Tool for Heart Health in Cancer Survivors
This trial is looking at the effects of a tool that uses electronic health records to help cancer survivors manage their cardiovascular health. The study will compare how well the tool works compared to usual care in terms of risk reduction and health promotion activities.
Small Molecule Inhibitor
RGX-202-01 Combination Therapy for Colorectal Cancer
This trial is testing a new drug, RGX-202-01, to see if it can shrink tumors in people with gastrointestinal cancer. The study will test different doses of the drug to see what is safe and effective. The study will also test the drug in combination with other drugs that are commonly used to treat gastrointestinal cancer.
Frequently Asked Questions
Introduction to bowel cancer
What are the top hospitals conducting bowel cancer research?
When it comes to cutting-edge clinical trials in the battle against bowel cancer, several top hospitals are making notable contributions. In New york City, Memorial Sloan Kettering Cancer Center leads the way with six active trials specifically focused on this condition, in addition to an impressive history of 70 completed trials spanning several decades since their first recorded bowel cancer trial in 1989. Moving over to Boston, Massachusetts General Hospital is also actively involved in advancing research for bowel cancer with four ongoing trials and a remarkable record of 71 completed studies since their inaugural trial in 2001.
Further south at Duke University Medical Center in Durham, researchers are currently conducting three active clinical trials for bowel cancer while having made significant progress through 33 previous investigations since initiating their first study back in 2003. Meanwhile, the National Institutes of Health Clinical Center located in Bethesda contributes its expertise as well, engaging four ongoing bowel cancer trials and contributing knowledge from a total of fourteen accomplished studies ever since they commenced research efforts targeting this disease back in1999.
Despite being relatively new to the scene compared to other institutions on this list, Norton Cancer Institute situated within Louisville plays a vital role by offering three current clinical trials for bowel cancer patients. Although still building up its portfolio with only four previously conducted investigations thus far (beginning just three years ago), Norton Cancer Institute shows great promise and dedication towards pushing boundaries for improved outcomes.
These leading hospitals collectively serve as beacons of hope not only for those affected by bowel cancer but also symbols of progress within the medical field globally. Each trial carried out brings us closer to understanding this complex disease better and developing more effective treatments that can potentially save lives around the world
Which are the best cities for bowel cancer clinical trials?
When it comes to bowel cancer clinical trials, several cities in the United States offer significant opportunities for research and advancements. Los Angeles, California leads with 18 active trials focusing on treatments like Eflornithine plus sulindac, tucatinib, and Ramucirumab. New york, New York follows closely behind with 17 ongoing studies exploring innovative approaches such as pralsetinib (BLU-667), GRT-C901, and Botensilimab/balstilimab (bot/bal). Additionally, Boston, Massachusetts contributes to the field with 11 active trials investigating JDQ443+trametinib and NUC-3373 among others. These cities serve as hubs of medical research for bowel cancer clinical trials that hold promise for improving treatment options and outcomes.
Which are the top treatments for bowel cancer being explored in clinical trials?
Bowel cancer research is steadily progressing, with a few promising treatments currently under exploration in clinical trials. One of the top contenders is tucatinib, which has one active trial and three all-time bowel cancer trials since its listing in 2020. Another treatment being investigated is ELU001, also with one ongoing trial and one all-time bowel cancer trial that was first listed in 2021. Additionally, EU101 shows potential as it enters the scene with one active trial and one all-time bowel cancer trial from 2021 onwards. As these trials progress, there is hope for advancements in treating this challenging disease.
What are the most recent clinical trials for bowel cancer?
Exciting advancements are being made in the field of bowel cancer research, with recent clinical trials exploring innovative approaches to treatment. A noteworthy trial is A2530, a combined Phase 1 and Phase 2 study that became available on 4/28/2023. Another promising investigation involves NUFIRI-bev administered on a Q1W NUC-3373 schedule for bowel cancer patients—this Phase 2 trial was accessible from 4/18/2023. Additionally, researchers have been studying the potential benefits of botensilimab and balstilimab (bot/bal) in treating bowel cancer in a separate Phase 2 trial initiated on 3/17/2023. These studies highlight the dedication to finding more effective therapies for those impacted by this disease.
What bowel cancer clinical trials were recently completed?
Recent clinical trials have made significant strides in advancing the treatment of bowel cancer. One noteworthy trial, sponsored by Mayo Clinic, focused on evaluating the efficacy of the Colorectal cancer Peptide Vaccine PolyPEPI1018 and was completed in January 2022. Another study conducted by Janssen Research & Development, LLC investigated JNJ-64251330 and concluded in November 2021. Additionally, Apros Therapeutics' APR003 trial reached completion in January 2021. These studies represent important contributions to our understanding of bowel cancer therapies and offer hope for improved treatments for patients battling this disease.